FOR US HEALTHCARE PROFESSIONALS ONLY

For adults living with schizophrenia
Repeated relapses and cycles of failure on oral antipsychotics can shatter lives

SYMPTOM STABILITY

CAN’T WAIT

See how INVEGA SUSTENNA^® can provide patients
with superior symptom control today

Rapid disease progression occurs within the first
3-5 years
post diagnosis^1,2

Delayed symptom control can lead to a dangerous downward trend of repeated relapses, worsening symptoms, and increasing disability for adults with schizophrenia^2,3

Achieving effective symptom control earlier after diagnosis is critical^1,2,4

Effective, sustained symptom control is the foundation of a comprehensive treatment plan, with medication being 1 part of a multipronged approach.^1,2

Earlier intervention with
INVEGA SUSTENNA® can help delay time to relapse^5-8

It's never too late to offer patients the consistent medication delivery of

once-monthly

INVEGA SUSTENNA^®.⁵

Did you know adults with schizophrenia are:

more likely to experience a negative housing change, such as becoming homeless, after 1 relapse⁹

more likely to be incarcerated after experiencing 1 relapse⁹

66.2^%

more likely to be unemployed with 1 relapse experience vs patients with no relapses⁹

A comprehensive treatment plan, which could include cognitive behavioral therapy and psychosocial services, can help patients address these challenges.

Help avoid
cycles of relapse
associated with daily orals. Prescribe INVEGA SUSTENNA^®—the #1 prescribed long-acting injectable.¹⁰

In a 15-month study with
a real-world* design:

INVEGA SUSTENNA^® was studied vs a group of 7 commonly prescribed oral antipsychotics^5,6†

See comparative results

In a 24-month
international^‡ study:

INVEGA SUSTENNA^® was studied vs a group of common oral antipsychotics in adults diagnosed with schizophrenia within 1 to 5 years⁷

See results in recently diagnosed patients

In a post hoc analysis of
these 2 studies:

The risk of relapse with INVEGA SUSTENNA^® in
adult patients was evaluated based on time since diagnosis (ranging from 0-5 years)⁸

See earlier use analysis

INVEGA SUSTENNA^® was evaluated in 4 short-term and 1 longer-term placebo-controlled trials⁵

See pivotal studies

*Real-world was defined by patient selection and clinically meaningful outcome measures.⁶

†The 7 oral antipsychotics included in the comparative arm accounted for 74% of oral schizophrenia treatment during the study period.¹¹

‡The study was conducted in 26 countries, excluding the United States.⁷

References: 1. Birchwood M. Early intervention and sustaining the management of vulnerability. Aust N Z J Psychiatry. 2000;34 Suppl:S181-184. 2. Tandon R, Nasrallah H, Akbarian S, et al. The schizophrenia syndrome, circa 2024: what we know and how that informs its nature. Schizophr Res. 2024;264:1-28. 3. Lieberman JA, Perkins D, Belger A, et al. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches [published correction appears in Biol Psychiatry. 2002;51(4):346]. Biol Psychiatry. 2001;50(11):884-897. 4. Lewis DA, Lieberman JA. Catching up on schizophrenia: natural history and neurobiology. Neuron. 2000;28(2):325-334. 5. INVEGA SUSTENNA^® [Prescribing Information]. Titusville, NJ: Janssen Pharmaceuticals, Inc. 6. Alphs L, Benson C, Cheshire-Kinney K, et al. Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia: a randomized, open-label, review board-blinded 15-month study. J Clin Psychiatry. 2015;76(5):554-561. 7. Schreiner A, Aadamsoo K, Altamura AC, et al. Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia. Schizophr Res. 2015;169(1-3):393-399. 8. Sajatovic M, Doring M, Lopena OJ, et al. Earlier use of long-acting injectable paliperidone palmitate once-monthly versus oral antipsychotics in patients with schizophrenia: an integrated patient-level meta analysis of the PROSIPAL and PRIDE studies. Neuropsychiatr Dis Treat. 2024;20:2227-2235. 9. Lin D, Joshi K, Keenan A, et al. Associations between relapses and psychosocial outcomes in patients with schizophrenia in real-world settings in the United States. Front Psychiatry. 2021;12:695672. 10. Data on file. Janssen Pharmaceuticals, Inc. 11. Data on file. Janssen Pharmaceuticals, Inc.

SYMPTOM STABILITY

CAN’T WAIT

Rapid disease progression occurs within the first 3-5 years post diagnosis1,2

Did you know adults with schizophrenia are:

Help avoid cycles of relapse associated with daily orals. Prescribe INVEGA SUSTENNA®—the #1 prescribed long-acting injectable.10

Rapid disease progression occurs within the first
3-5 years
post diagnosis^1,2

Help avoid
cycles of relapse
associated with daily orals. Prescribe INVEGA SUSTENNA^®—the #1 prescribed long-acting injectable.¹⁰